Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

被引：0
作者：
Shitara, Kohei
Xu, Rui-Hua
Moran, Diarmuid Martin
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob P.
Ajani, Jaffer A.
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4035
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).
    Qi, Changsong
    Liu, Chang
    Gong, Jifang
    Li, Jian
    Liu, Dan
    Ge, Sai
    Zhang, Miao
    Peng, Zhi
    Zhou, Jun
    Zhang, Xiaotian
    Zheng, Ji
    Xiao, Jun
    Yuan, Daijing
    Peng, Yueying
    Wang, Huamao
    Li, Zonghai
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin 18.2+/HER2-advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
    Shah, Manish A.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shitara, Kohei
    Van Cutsem, Eric
    Arozullah, Ahsan
    Park, Jung Wook
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium
    Mackay, H.
    Au, H.
    McWhirter, E.
    Alcindor, T.
    Jarvi, A.
    MacAlpine, K.
    Wang, L.
    Wright, J. J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.
    Shen, Lin
    Peng, Zhi
    He, Ying
    Chen, Jing
    Hickingbottom, Barbara
    Lu, Jianfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 317 - 317
  • [45] Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Llimpe, F. L. Rojas
    Cascinu, S.
    Giaquinta, S.
    Schinzari, G.
    Mutri, V.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Real-world biomarker testing and first-line treatment patterns among locally advanced, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma patients in the US.
    Wellen, Maria
    Luu, Tony
    Gleason, Michelle Kathleen
    Majer, Istvan Matyas
    Reading, Stephanie Rummans
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 348 - 348
  • [47] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Schuler, M.
    Al-Batran, S-E.
    Zvirbule, Z.
    Manikhas, G.
    Lordick, F.
    Rusyn, A.
    Vinnyk, Y.
    Vynnychenko, I.
    Fadeeva, N.
    Nechaeva, M.
    Dudov, A.
    Gotovkin, E.
    Pecheniy, A.
    Bazin, I.
    Bondarenko, I.
    Melichar, B.
    Huber, C.
    Tuereci, Oe.
    Sahin, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Talia, Golan
    Lin Chia-Chi
    Fu Siqing
    Heather, Wasserstrom
    Mi Gu
    Naomi, Laing
    Maria, Karasarides
    Yung-Jue, Bang
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Conversion effect of PD-1 antibody camrelizumab (Cam) combined with modified FLOT (mFLOT) regimen in patients( pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Geng, Q.
    Feng, W.
    Huang, H.
    Zhao, X.
    Fu, H.
    Zhou, Y.
    Zhang, W.
    Huang, M.
    Zhao, G.
    Xu, D.
    Guo, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S882 - S882
12345